| OTLK Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the OTLK shares outstanding history going back to 8/10/2018:
Also see: OTLK Market Cap History OTLK YTD Return |
OTLK Shares Outstanding History — Outlook Therapeutics Share Count Over Time
As of 2/13/2026 Outlook Therapeutics has 83.07 million OTLK shares outstanding. Investors often track the OTLK shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows OTLK share count trends over time, with 36 historical shares outstanding datapoints presented, dating back to 8/10/2018.
| OTLK Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OTLK Historical Shares Outstanding: +100.12% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| OTLK Stock Price Chart |
| About Outlook Therapeutics Inc |
| Outlook Therapeutics, Inc. is a biopharmaceutical company. Co. focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. Co.'s product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. We show 36 historical shares outstanding datapoints in our coverage of OTLK's shares outstanding history. Understanding the changing numbers of OTLK shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like OTLK versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching OTLK by allowing them to research OTLK shares outstanding history as well as any other stock in our coverage universe. |
| OTLK Current Stock Quote |
Quotes delayed 20 minutes  Free OTLK Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| OTLK Share Performance |
| Shares Outstanding Peers |
| Outlook Therapeutics (OTLK) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
OTRK Shares Outstanding History OVAS Shares Outstanding History OVID Shares Outstanding History OWLT Shares Outstanding History OYST Shares Outstanding History PACB Shares Outstanding History PACS Shares Outstanding History PAHC Shares Outstanding History PALI Shares Outstanding History PAND Shares Outstanding History More Healthcare companies » |
OTLK Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
